Brentjens on the Next Chapter of CAR T-Cell Therapy in Relapsed/Refractory Multiple Myeloma

Season 7 Episode 37  ·  Oct 10, 2022, 06:32 PM

Headliner
Share
Subscribe

Dr Brentjens discusses targeting the “enigmatic” GPRC5D protein, safety results with MCARH109, and the appropriate sequencing for the agent.

Share
Subscribe
Next
FDA Approval Insights: Selpercatinib in RET Fusion–Positive Solid Tumors
Top episodes
DeNunzio Describes the Advantages of Proton Beam Therapy in Oncology
by OncLive® On Air
FDA Approval Insights: Amivantamab and Mobocertinib in EGFR Exon 20 Insertion+ NSCLC
by OncLive® On Air
Milhem Talks Mechanism of Action, Delivery Methodology, and Ongoing Trials With RP1
by OncLive® On Air